UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000061660
Receipt number R000070552
Scientific Title Exploratory Study of Yogurt Consumption and Salivary IgA Using Existing Saliva Specimens
Date of disclosure of the study information 2026/05/24
Last modified on 2026/05/22 15:37:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Exploratory Study of Yogurt Consumption and Salivary IgA Using Existing Saliva Specimens

Acronym

Exploratory Study of Yogurt Consumption and Salivary IgA Using Existing Saliva Specimens

Scientific Title

Exploratory Study of Yogurt Consumption and Salivary IgA Using Existing Saliva Specimens

Scientific Title:Acronym

Exploratory Study of Yogurt Consumption and Salivary IgA Using Existing Saliva Specimens

Region

Japan


Condition

Condition

Healthy Adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effect of yogurt intake on salivary IgA production.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Salivary IgA cross-reacts with respiratory viruses

Key secondary outcomes



Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

35 years-old <=

Age-upper limit

60 years-old >

Gender

Male and Female

Key inclusion criteria

Subjects examined in the other study (UMIN000053187)

Key exclusion criteria

1) Subjects who expressed their intention to withdraw from the study after the disclosure of information regarding its conduct
2) Subjects from whom no saliva sample was obtained during the initial examination

Target sample size

140


Research contact person

Name of lead principal investigator

1st name Takayuki
Middle name
Last name Toshimitsu

Organization

Meiji Co., Ltd.

Division name

R and D division

Zip code

192-0919

Address

1-29-1 Nanakuni, Hachiouji, Tokyo, Japan

TEL

81-80-1057-4299

Email

takayuki.toshimitsu@meiji.com


Public contact

Name of contact person

1st name Takayuki
Middle name
Last name Toshimitsu

Organization

Meiji Co., Ltd.

Division name

R and D division

Zip code

192-0919

Address

1-29-1 Nanakuni, Hachiouji, Tokyo, Japan

TEL

81-80-1057-4299

Homepage URL


Email

takayuki.toshimitsu@meiji.com


Sponsor or person

Institute

Meiji Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Meiji Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Meiji Institutional Review Board

Address

1-29-1 Nanakuni, Hachiouji, Tokyo, Japan

Tel

81-42-632-5900

Email

MEIJI.IRB@meiji.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 05 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 05 Month 11 Day

Date of IRB

2026 Year 05 Month 13 Day

Anticipated trial start date

2026 Year 05 Month 25 Day

Last follow-up date

2026 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

None


Management information

Registered date

2026 Year 05 Month 22 Day

Last modified on

2026 Year 05 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070552